Senju Pharmaceutical
As of the edition of 20 October 2026, Senju Pharmaceutical runs 10 drugs, 7 of them marketed; it is on route A at 1 target and on route B at 8 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Went quiet | 1 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ibuprofen | none listed | 11 |
| Azithromycin | none listed | 0 |
| Timolol | none listed | 5 |
| Brimonidine | none listed | 9 |
| Bimatoprost | Ends 2031 (patent) | 3 |
| Brinzolamide | none listed | 3 |
| Motugivatrep | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 8 targets.
All 9 rows on route A or B
In the product9 company-target rows on route A or B; 6 are not shown here, and no score is.
See all 9 targets where Senju Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Eye: 3 trials led